HCPCS code J1786: Billing imiglucerase (Cerezyme) for Gaucher disease

Key takeaways

HCPCS code J1786 describes injection, imiglucerase, 10 units. It bills Cerezyme enzyme replacement therapy for Gaucher disease Type 1 and the non-CNS manifestations of Type 3.

Each billed unit equals 10 units of imiglucerase. Divide the prescribed dose in units by 10 to get the J1786 unit count for the claim.

Medicare Part B reimburses J1786 at ASP+6%, recalculated quarterly. ICD-10 code E75.22 belongs on every claim to establish medical necessity.

Practice management software like Pabau automates unit calculations, NDC reporting, and eligibility checks, so infusion claims submit clean the first time.

HCPCS code J1786 is the HCPCS Level II J-code for injection, imiglucerase, 10 units. It bills the drug given in a Cerezyme infusion, and one billed unit covers 10 units of imiglucerase.

Three fields decide whether the claim pays. Divide the prescribed dose by 10 to get the unit count, and report E75.22 as the diagnosis. Then pair the drug with the administration CPT code your MAC accepts. Medicare Part B then pays the Average Sales Price plus 6%, recalculated every quarter.

HCPCS code J1786: Definition, descriptor, and code details

HCPCS code J1786 is the Level II code assigned by CMS to describe injection, imiglucerase, 10 units. J-codes classify drugs given by a route other than oral. J1786 covers the intravenous infusion of imiglucerase, the recombinant glucocerebrosidase that Sanofi Genzyme sells under the brand name Cerezyme.

The code is active for the 2026 fiscal year with no descriptor changes from prior years. CMS maintains it in the HCPCS Level II J-code category and revises it through the annual HCPCS update cycle, not through the AMA CPT process.

Clinical context: Gaucher disease and imiglucerase

Gaucher disease is the most common lysosomal storage disorder. In Type 1, the non-neuronopathic form, a deficiency of glucocerebrosidase lets glucocerebroside build up in macrophages of the spleen, liver, and bone marrow. Imiglucerase is a recombinant form of that enzyme, given as long-term enzyme replacement therapy.

The FDA expanded the imiglucerase label in January 2026. It now covers Type 1 Gaucher disease and the non-CNS manifestations of Type 3. Type 2 and the neurologic features of Type 3 stay outside the approved indication. A J1786 claim tied to CNS involvement can still draw medical necessity scrutiny.

Dosing is weight-based and patient-specific. Labeling runs from 2.5 units per kilogram three times a week up to 60 units per kilogram once every two weeks.

Because the dose varies that widely, the units billed under J1786 differ from patient to patient and from infusion to infusion. Never apply a standard dose to J1786 billing without checking the prescribed dose in the clinical record.

• Diagnosis required: Confirmed Gaucher disease by enzyme assay or molecular genetic testing
• Indication: Long-term enzyme replacement therapy, typically lifelong
• Administration: Intravenous infusion, usually 1 to 2 hours in an infusion center or outpatient setting
• Manufacturer: Sanofi Genzyme, and Cerezyme is the only imiglucerase brand sold in the US
• Approved scope: Type 1 Gaucher disease and the non-CNS manifestations of Type 3. J1786 does not support Type 2 or CNS symptoms, which sit outside the label.

J1786 billing units and dosage calculation

One unit of J1786 represents 10 units of imiglucerase. To find the number of J1786 units to report, divide the prescribed dose in units of imiglucerase by 10. Round to the nearest whole number.

Verify the prescribed dose against the clinical documentation before submitting. Billing more units than the documented dose is an overcoding error, and billing fewer leaves reimbursement on the table. Cerezyme is expensive and the doses are large, so a one-unit discrepancy per claim adds up over a treatment course.

ICD-10 diagnosis codes that support medical necessity for J1786

Every J1786 claim needs a supporting ICD-10-CM diagnosis code to establish medical necessity. Without a valid Gaucher disease diagnosis code, the claim denies. The primary code is E75.22, and a small set of related codes may apply depending on the clinical presentation documented.

E75.22 is the only ICD-10-CM code that maps directly to Gaucher disease, and Medicare and most commercial payers accept it with J1786. Some MAC Local Coverage Determinations list E75.22 as the sole covered diagnosis, so defaulting to it on every imiglucerase claim is the safest habit. Always confirm whether a payer’s coverage policy has expanded or restricted the list.

If the documentation names a different sphingolipidosis, our ICD-10-CM code reference covers the rest of the E75 family.

Companion CPT codes for imiglucerase infusion

J1786 covers the drug only. The administration service billed alongside it needs a separate CPT code. Most commercial and Medicare claims for imiglucerase infusion use the therapeutic drug infusion codes. The choice turns on infusion duration and on whether sequential infusions follow the initial dose.

Verify which administration code set your Medicare Administrative Contractor requires for imiglucerase specifically. Some MACs treat the infusion under the 96365 and 96366 series rather than 96413 and 96415. Submitting the wrong administration code alongside J1786 is a common source of claim edits. Check current AMA CPT guidance and your MAC’s coverage policy first.

NDC crosswalk for J1786 claims

Medicaid programs and many commercial payers require a National Drug Code at the line level on claims that include J1786. Medicare does not require NDC reporting on the CMS-1500, though individual MACs may request it for review. Always report the NDC from the vial actually administered, not a generic lookup value.

Cerezyme comes in a single strength of 400 units per vial from Sanofi Genzyme. NDC numbers can change with new manufacturing lots or packaging. The NDC below was current at the time of writing, so verify it against the Sanofi Genzyme package insert or FDA label before submitting claims.

Medicare reimbursement and fee schedule for J1786

Medicare Part B reimburses J1786 at the Average Sales Price plus 6%. CMS updates ASP pricing quarterly, so the allowable rate changes four times a year. Check the current CMS ASP Drug Pricing File before each quarter’s billing cycle. CMS’s Physician Fee Schedule lookup tool shows the current allowable by locality.

Imiglucerase is among the most expensive physician-administered drugs in the Part B portfolio. Because payment is set per 10 units, the unit count has to be exact to capture the full allowable. Underbilling by 10 units on a 400-unit dose costs 2.5% of the infusion, on what is usually a biweekly, lifelong schedule.

Between the quarterly ASP update lag and the buy-and-bill acquisition cost, cash flow on a Gaucher disease infusion program needs close attention. Expect a gap of weeks between paying for the drug and collecting the allowable on it.

Buy-and-bill model for imiglucerase

Imiglucerase is almost always dispensed through the buy-and-bill model in office-based and infusion center settings. The provider purchases Cerezyme from Sanofi Genzyme or a specialty distributor, administers it, and then bills the payer using J1786. Under specialty pharmacy dispensing, by contrast, the pharmacy bills for the drug and the provider bills only the administration service.

1. Acquire: Order Cerezyme from Sanofi Genzyme or an authorized specialty distributor. Confirm the vial count against the patient’s prescribed dose and administration schedule.
2. Verify eligibility: Confirm coverage and any active prior authorization before each infusion session. Authorizations expire, so reverifying at the start of each period prevents surprise denials.
3. Administer: Infuse per the prescribing physician’s protocol. Document the start and end time, which drives the administration code, plus the lot number and the exact units given.
4. Submit the claim: Report J1786 with the correct unit count and E75.22 as the primary diagnosis. Add the companion administration CPT code, the place of service code, and the NDC where the payer requires it.
5. Reconcile payment: Compare the Medicare remittance advice against the submitted claim. Check that the units reimbursed match the units billed, and flag any contractual adjustment that looks wrong.

Buy-and-bill creates working capital exposure, because the provider pays for the drug upfront and waits for reimbursement. A single Cerezyme vial costs thousands of dollars, so even a small Gaucher disease patient panel belongs in the practice’s cash flow planning.

Commercial payer and Medicaid coverage for J1786

Coverage under commercial insurance and state Medicaid programs varies materially from Medicare’s standardized ASP+6% approach. Most commercial payers cover J1786 where medical necessity is documented and prior authorization is in place. Reimbursement rates, quantity limits, and approved care settings still differ by plan.

Medicaid coverage is state-administered. Some state programs use a state-specific maximum allowable cost that sits below Medicare’s ASP+6%. Others run through managed Medicaid plans that apply their own prior authorization criteria. Never assume Medicaid approval or a specific rate without checking the applicable state fee schedule portal.

California’s Medi-Cal, for example, has issued HCPCS policy updates governing J-code infusion billing that differ from standard Medicare rules.

Prior authorization requirements for J1786

Commercial payers and Medicaid plans generally require prior authorization before the first imiglucerase infusion. Medicare does not require it for J1786, but the coverage criteria in the applicable LCD still have to be met and documented. For commercial patients, a missing authorization at the time of administration is the single largest cause of J1786 denials.

Most authorization requests for Cerezyme ask for documentation across several clinical areas. Organizing these in advance speeds approval and reduces the risk of a denied infusion session.

• Confirmed diagnosis: Laboratory confirmation of Gaucher disease by enzyme assay or genetic testing
• Prescribing physician credentials: Some payers require that imiglucerase be prescribed by, or in consultation with, a specialist in metabolic or lysosomal storage disorders
• Clinical necessity documentation: Evidence of symptomatic disease, such as hepatosplenomegaly, cytopenias, bone involvement, or growth failure in pediatric patients
• Dose justification: Weight-based dose calculation, with the patient’s weight documented in the clinical record
• Treatment setting: An approved place of service, meaning an infusion center, physician office, or outpatient hospital
• Authorization period: Most commercial authorizations run 6 or 12 months. Note the expiration date and start the renewal at least 30 days before it lapses.

Sound denial management for J1786 starts with authorization tracking. When an authorization lapses, or the dose changes without re-authorization, the claim denies even though the underlying coverage exists. Build a renewal reminder into the workflow calendar, tied to each patient’s expiration date.

Place of service and applicable modifiers

The place of service code on the J1786 claim decides whether Medicare and commercial payers apply the facility or non-facility rate. Imiglucerase is infused in several settings, and the code has to reflect where the service was rendered.

Two modifiers come up on J1786 claims. Modifier JW reports the discarded portion of a vial when the dose does not use all 400 units. Modifier JZ reports zero waste where payer rules call for it. Omitting JW when waste occurs can trigger an overpayment audit, and omitting JZ where it is required delays the claim.

Common billing errors and how to avoid them

J1786 claims are high-dollar and high-scrutiny. Errors compound quickly, because the drug is expensive, the doses are large, and the treatment is indefinite. Eight data elements decide the outcome of the drug line, and the ones below are where audits and denial patterns concentrate.

• Wrong unit count: Dividing the dose by the wrong denominator, or billing in milligrams instead of units. Always divide prescribed imiglucerase units by 10.
• Missing or incorrect NDC: Omitting the NDC on Medicaid claims, or using a lookup value instead of the number on the vial. Read it off the vial label.
• No ICD-10 on the claim: Submitting J1786 without E75.22 or another payer-accepted Gaucher disease code. Every claim line needs a diagnosis pointer.
• Expired prior authorization: Administering imiglucerase after a commercial or Medicaid authorization has lapsed. Set renewal reminders 30 days out.
• Wrong companion CPT code: Using 96365 where the MAC requires 96413, or the reverse. Confirm against the coverage policy and any payer-specific infusion rules.
• Incorrect POS code: Reporting POS 11 when the infusion happened in a hospital outpatient department. The code must match the administration site.
• Missing drug waste modifier: Leaving JW off a claim where a partial vial was discarded. That is a compliance problem and a missed chance to capture wasted drug cost.

A pre-claim checklist covering units, NDC, ICD-10, authorization status, companion CPT, place of service, and the waste modifier removes most of these errors. Pabau’s claims management software builds those checks into the submission workflow, so no one verifies eight fields from memory on every infusion.

How claims management software keeps J1786 claims clean

Most infusion practices assemble a J1786 claim from separate places. The dose sits in the clinical note, the vial’s NDC sits on a paper log, and the authorization expiry sits in a spreadsheet. A coder then reconciles all three before the claim goes out.

Practice management software like Pabau keeps those records in one patient file instead. The infusion note, the administered units, the NDC, and the authorization dates travel with the claim. The billing team submits from the record rather than retyping it.

The result is fewer unit mismatches, fewer lapsed authorizations, and a shorter path from infusion to payment. A claim that carries its own documentation clears the first submission more often, which matters most on a drug this expensive.

Streamline specialty drug billing from infusion to payment

Pabau’s claims management tools help infusion practices track administered drug units and attach NDC data. J-code claims go out with the documentation payers need to pay them the first time.

Book a demo

Conclusion

Billing J1786 accurately takes more than knowing the code. The unit count, the NDC, the companion CPT code, the authorization status, and the waste modifier all have to be right on the same line. That holds on every infusion, not only the first.

The trade-off worth remembering is scale. One systematic error on a lifelong biweekly schedule costs far more than a single slip. The correction belongs in the workflow, not in a reviewer’s memory. Audit a quarter of J1786 claims against the clinical documentation and you will know which kind you have.

Book a demo to see how Pabau carries administered drug units and authorization dates through to the claim.

Continue your research

Need a framework for managing claim denials on specialty drugs? Denial management in healthcare covers the workflows and tracking that keep J-code rejections from aging into write-offs.

Want to see how revenue cycle management works for Part B drugs? Revenue cycle management fundamentals explains the billing cycle from drug acquisition through final payment.

Looking for guidance on clean claims for specialty infusions? What makes a clean claim outlines the documentation and data that reduce edit holds on high-dollar submissions.

Frequently asked questions